61.7% of patients on seladelpar 10 mg achieved the primary composite endpoint vs. 20.0% of patients on placebo (p<0.0001)
Seladelpar achieved a highly significant rate of alkaline phosphatase normalization and reductions in patient-reported pruritus vs. placebo
The results will support the submission of global market authorization applications
NEWARK, Calif., Nov. 13, 2023 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the results from its RESPONSE Phase 3 registration study evaluating seladelpar, a potent, selective, orally-active delpar, or PPAR